Yiheng Capital Management L.P. Sells 2,497,267 Shares of DBV Technologies S.A. (NASDAQ:DBVT)

Yiheng Capital Management L.P. lowered its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 79.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 656,309 shares of the company’s stock after selling 2,497,267 shares during the quarter. DBV Technologies makes up approximately 0.1% of Yiheng Capital Management L.P.’s portfolio, making the stock its 16th largest holding. Yiheng Capital Management L.P.’s holdings in DBV Technologies were worth $2,028,000 as of its most recent SEC filing.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. JMP Securities restated a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research report on Friday, January 10th. StockNews.com started coverage on shares of DBV Technologies in a report on Friday, March 14th. They issued a “hold” rating on the stock.

DBV Technologies Price Performance

Shares of DBVT opened at $5.28 on Friday. The firm’s 50 day simple moving average is $4.47 and its 200 day simple moving average is $3.84. The company has a market capitalization of $108.60 million, a P/E ratio of -1.17 and a beta of 0.71. DBV Technologies S.A. has a 1-year low of $2.20 and a 1-year high of $8.32.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.